BIRTH DEFECTS: THE ROLE OF P-GLYCOPROTEIN
- Authors: Pikuza T.V1, Chilova R.A1, Sokova E.A1,2, Kazakov R.E2, Akopov K.O3, Astsaturova O.R1
-
Affiliations:
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
- Scientific Centre for Expert Evaluation of Medicinal Products
- State Clinical Hospital named. S.S. Yudina
- Issue: Vol 31, No 7 (2020)
- Pages: 27-33
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/114255
- DOI: https://doi.org/10.29296/25877305-2020-07-04
- ID: 114255
Cite item
Abstract
Full Text
About the authors
T. V Pikuza
I.M. Sechenov First Moscow State Medical University (Sechenov University)Moscow
R. A Chilova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Email: rchilova@gmail.com
Professor, MD Moscow
E. A Sokova
I.M. Sechenov First Moscow State Medical University (Sechenov University); Scientific Centre for Expert Evaluation of Medicinal ProductsCandidate of Medical Moscow
R. E Kazakov
Scientific Centre for Expert Evaluation of Medicinal ProductsCandidate of Biological Sciences Moscow
K. O Akopov
State Clinical Hospital named. S.S. YudinaMoscow
O. R Astsaturova
I.M. Sechenov First Moscow State Medical University (Sechenov University)Candidate of Medical Sciences Moscow
References
- Oza S., Lawn J.E., Hogan D.R. et al. Neonatal cause-of-death estimates for the early and late neonatal periods for 194 countries: 2000-2013. Bull World Health Organ. 2015; 93 (1): 19-28. doi: 10.2471/BLT.14.139790
- United Nations Inter-agency Group for Child Mortality Estimation (UN IGME). Levels & Trends in Child Mortality. New York: UNICEF, 2017.
- Демикова Н.С., Лапина А.С. Врожденные пороки развития в регионах Российской Федерации (итоги мониторинга за 2000-2010 гг.). Рос вестн перинатол и педиатр. 2012; 57 (2): 91-8
- Feldkamp M.L., Carey J.C., Byrne J.L.B. et al. Etiology and clinical presentation of birth defects: population based study. BMJ. 2017; 357. doi: 10.1136/bmj.j2249
- Holmes L.B., Westgate M.-N., Toufaily M.H. Malformations attributed to the process of vascular disruption. Birth Defects Res. 2018; 110: 98-107. doi: 10.1002/bdr2.1160
- Toufaily MH, Westgate Marie-Noel, Lin AE, et al. Research Article Causes of Congenital Malformations. Birth Defects Research. 2018; 110: 87-91. doi: 10.1002/bdr2.1105
- Tomson T., Battino D., Bonizzoni E. et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018; 17: 530-8. DOI: 10.1016/ S1474-4422(18)30107-8
- Klausner R., Shapiro E.D., Elder R.W. Evaluation of a Screening Program to Detect Critical Congenital Heart Defects in Newborns. Hosp Pediatr. 2017; 7(4): 214-218. doi: 10.1542/hpeds.2016-0176
- EUROCAT - European Surveillance of Congenital Anomalies. Publication of the EUROCAT statistical monitoring report and updated prevalence tables. Available from: http://www.eurocat-network.eu/ (last accessed: 21 September 2016).
- Zhu H., Kartiko S., Finnell R.H. Importance of gene - environment interactions in the etiology of selected birth defects. Clin Genet. 2009; 75 (5): 409-23. doi: 10.1111/j.1399-0004.2009.01174.x
- Atkinson D., Brice-Bennet S., D’souza S.W. Antiepileptic Medication During Pregnancy: Does Fetal Genotype Affect Outcome? Pediatric research. 2007; 62 (2): 120-7. doi: 10.1203/PDR.0b013e3180a02e50
- Guideline on the exposure to medicinal products during pregnancy: need for post authorisation. EMEA/CHMP/313666/2005, London, 14 November, 2005.
- Персонализированная медицина: клинико-фармакологические аспекты. Под ред. В.Г. Кукеса. М.: Издательство АГО Международная ассоциация клинических фармакологов и фармацевтов, 2014; 260 с.
- Кукес В.Г., Сокова Е.А., Игнатьев И.В. и др. Гликопротеин Риздоровье плода. Проблемы репродукции. 2010; 5: 78-84
- Daud A.N.A., Bergman J.E.H., Kerstjens-Frederikse W.S. et al. Prenatal exposure to serotonin reuptake inhibitors and congenital heart anomalies: an exploratory pharmacogenetics study. Pharmacogenomics. 2017; 18 (10): 9871001. doi: 10.2217/pgs-2017-0036
- Bloise E., Ortiga-Carvalho T.M., Reis F.M. et al. ATP-binding cassette transporters in reproduction: a new frontier. Hum Reprod Update. 2016; 22: 16481. doi: 10.1093/humupd/dmv049
- Brayboy L.M., Oulhen N., Long S. et al. Multidrug resistance transporter-1 and breast cancer resistance protein protect against ovarian toxicity, and are essential in ovarian physiology. Reprod Toxicol. 2017; 69: 121-31. DOI: 10.1016/j. reprotox.2017.02.002
- Brayboy L.M., Knapik L.O., Long S. et al. Ovarian hormones modulate multidrug resistance transporters in the ovary. Contraception and Reproductive Medicine. 2018; 3: 26. doi: 10.1186/s40834-018-0076-7
- Helguera G., Eghbali M., Sforza D. et al. Changes in global gene expression in rat myometrium in transition from late pregnancy to parturition. Physiol Genomics. 2009; 36: 89-97. doi: 10.1152/physiolgenomics.00290.2007
- Bloise E., Feuer S.K., Rinaudo P.F. Comparative intrauterine development and placental function of ART concepti: implications for human reproductive medicine and animal breeding. Hum Reprod Update. 2014; 20: 822-39. doi: 10.1093/humupd/dmu032
- Bleier B.S., Nocera A.L., Iqbal H. et al. P-glycoprotein functions as an immunomodulator in healthy human primary nasal epithelial cells. Int Forum Allergy Rhinol. 2013; 3 (6): 433-8. doi: 10.1002/alr.21166
- Iqbal M, Audette MC, Petropoulos S, et al. Placental drug transporters and their role in fetal protection. Placenta. 2012; 33: 137-42. DOI: 10.1016/j. placenta.2012.01.008
- Sawicki W.T., Kujawa M., Jankowska-Steifer E. et al. Temporal/spatial expression and efflux activity of ABC transporter, P-glycoprotein/Abcb1 isoforms and Bcrp/Abcg2 during early murine development. Gene Expr Patterns. 2006; 6: 738-46. doi: 10.1016/j.modgep.2005.12.003
- Joshi A.A., Vaidya S.S., St-Pierre M.V. et al. Placental ABC Transporters: Biological Impact and Pharmaceutical Significance. Pharm Res. 2016; 33 (12): 2847-78. doi: 10.1007/s11095-016-2028-8
- Koren Gideon, Ornoy Asher. The role of the placenta in drug transport and fetal drug exposure. Expert Review of Clinical Pharmacology. 2018; 11 (4): 373-85. doi: 10.1080/17512433.2018
- Han L.W., Gao C., Mao Q. An update on expression and function of P-gp/ ABCB1 and BCRP/ABCG2 in the placenta and fetus. Exp Opin Drug Metabol Toxicol. 2018; 14 (8): 817-29. doi: 10.1080/17425255.2018.1499726
- Sharom F.J. Complex interplay between the P-glycoprotein multidrug efflux pump and the membrane: its role in modulating protein function. Front Oncol. 2014; 4: 41. doi: 10.3389/fonc.2014.00041
- Lye Р., Bloise Е., Nadeem L, et al. Glucocorticoids modulate multidrug resistance transporters in the first trimester human placenta. Cell Mol Med. 2018; 22 (7): 3652-60. doi: 10.1111/jcmm.13646
- Marzolini C., Rudin C., Decosterd L.A. et al. Transplacental passage of protease inhibitors at delivery. Aids. 2002; 16 (6): 889-93. doi: 10.1097/00002030200204120-00008
- Imperio G.E., Javam М., Lye Р. et al. Gestational age-dependent gene expression profiling of ATP-binding cassette transporters in the healthy human placenta. J Cell Mol Med. 2019; 23: 610-8. doi: 10.1111/jcmm.13966
- Bruhn O., Cascorbi I. Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance. Exp Opin Drug Metab Toxicol. 2014; 10 (10): 1337-54. doi: 10.1517/17425255.2014.952630
- Hitzl M., Schaeffeler E., Hocher B. et al. Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1). Pharmacogenetics. 2004; 14: 309-18. doi: 10.1097/00008571-200405000-00006
- Obermann-Borst S.A., Isaacs A., Younes Z. et al. General maternal medication use, folic acid, the MDR1 C3435T polymorphism, and the risk of a child with a congenital heart defect. Am J Obstet Gynecol. 2011; 204 (3): 236.e1-8. doi: 10.1016/j.ajog.2010.10.911
- Frigerio B., Bizzoni C., Jansen G. et al. Folate receptors and transporters: biological role and diagnostic/therapeutic targets in cancer and other diseases. J Exp Clin Cancer Res. 2019; 38 (1): 125. doi: 10.1186/s13046-019-1123-1
- Lankas G.R., Wise L.D., Cartwright M.E. et al. Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reprod Toxicol. 1998; 12 (4): 457-63. doi: 10.1016/S0890-6238(98)00027-6
- Smit J.W., Huisman M.T., van Tellingen O. et al. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J Clin Invest. 1999; 104 (10): 1441-7. doi: 10.1172/JCI7963
- Staud F., Cerveny L., Ceckova M. Pharmacotherapy in pregnancy: effect of ABC and SLC transporters on drug transport across the placenta and fetal drug exposure. J Drug Target. 2012; 20: 736-63. doi: 10.3109/1061186X.2012.716847
- Daud A.N.A., Bergman J.E.H., Bakker M.K. et al. Pharmacogenetics of drug-induced birth defects: The role of polymorphisms of placental transporter proteins. Pharmacogenomics. 2014; 15 (7): 1029-41. doi: 10.2217/pgs.14.62
- Bliek B.J., van Schaik R.H.N., van der Heiden I.P. et al. Maternal medication use, carriership of the ABCB1 3435C > T polymorphism and the risk of a child with cleft lip with or without cleft palate. Am J Med Genet A. 2009; 149A (10): 2088-92. doi: 10.1002/ajmg.a.33036
- Martinelli M., Carinci F., Morselli P.G. et al. Study of ABCB1 multidrug resistance protein in a common orofacial malformation. Int J Immunopathol Pharmacol. 2011; 24: 1-5. doi: 10.1177/03946320110240S201
- Wang C., Zhou K., Xie L. et al. Maternal Medication Use, Fetal 3435 C>T Polymorphism of the ABCB1 Gene, and Risk of Isolated Septal Defects in a Han Chinese Population. Pediatr Cardiol. 2014; 35 (7): 1132-41. doi: 10.1371/journal. pone.0068807
- Omoumi A., Wang Z., Yeow V. et al. Fetal polymorphisms at the ABCB1-transporter gene locus are associated with susceptibility to non-syndromic oral cleft malformations. Eur J Hum Genet. 2013; 21(12): 1436-41. DOI: 10.1038/ ejhg.2013.25